Study the Role of the Efflux Pump in Multidrug-Resistant Acinetobacter baumannii
Article Sidebar
Main Article Content
Abstract
Thirty-one A. baumannii isolates were obtained from Shar and Burn hospitals in Sulaimani City, KRG-Iraq. Bacterial identification was confirmed by detecting both 16S rRNA and blaOXA-51 genes. The detection of carbapenem resistant isolates was carried out using Kirby- Bauer, RAPDEC Carba NP and combined disc assays. A high rate of drug resistance was observed, as 74.2% of the isolates were multidrug-resistant (MDR) and 38.7% were extensively drug-resistant (XDR), while carbapenem-resistant A. baumannii (CRAB) comprised approximately 58% of the isolates. Among CRAB isolates, carbapenemase production was detected by using the RAPDEC Carba NP and the combined disc assays in 88.8% (16/18) and 55.5% (10/18) of the isolates respectively. Phenotypic activity of efflux pump was detected among 22.5% of all isolates and 38.8% of CRAB isolates. PCR successfully identified the adeA, adeB, adeC, adeR, and adeS genes in 83.9%, 90.3%, 58%, 80.6%, and 90.3% of the isolates, respectively.
Eight mutations in adeR and 15 mutations in adeS regulatory genes were recorded. We conclude that carbapenem resistance mechanisms in A. bumanni isolates included mutations in adeRS regulatory genes and production of carbapenemase.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] M. Amin, T. Navidifar, F. S. Shooshtari, M. Rashno, M. Savari, F. Jahangirmehr, et al., "Association between biofilm formation, structure, and the expression levels of genes related to biofilm formation and biofilm-specific resistance of Acinetobacter baumannii strains isolated from burn infection in Ahvaz, Iran," Infection and Drug Resistance, vol. 12, p. 3867, 2019.
[2] G. S. GIEBINK, "Otitis media: the Chinchilla model1," Microbial drug resistance, vol. 5, pp. 57-72, 1999.
[3] H. Li, X. Wang, Y. Zhang, C. Zhao, H. Chen, S. Jiang, et al., "The role of RND efflux pump and global regulators in tigecycline resistance in clinical Acinetobacter baumannii isolates," Future microbiology, vol. 10, pp. 337-346, 2015.
[4] L. Azimi, A. E. Namvar, A. R. Lari, and S. Jamali, "Comparison of efflux pump involvement in antibiotic resistance among Pseudomonas aeruginosa isolates of burn and non-burn patients," Archives of Pediatric Infectious Diseases, vol. 4, 2016.
[5] É. Ruppé, P.-L. Woerther, and F. Barbier, "Mechanisms of antimicrobial resistance in Gram-negative bacilli," Annals of intensive care, vol. 5, pp. 1-15, 2015.
[6] E.-J. Yoon, P. Courvalin, and C. Grillot-Courvalin, "RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii:
major role for AdeABC overexpression and AdeRS mutations," Antimicrobial agents and chemotherapy, vol. 57, pp. 2989-2995, 2013.
[7] A. Y. Peleg, H. Seifert, and D. L. Paterson, "Acinetobacter baumannii: emergence of a successful pathogen," Clinical microbiology reviews, vol. 21, pp. 538-582, 2008.
[8] D. B. Knight, S. D. Rudin, R. A. Bonomo, and P. N. Rather, "Acinetobacter nosocomialis: defining the role of efflux pumps in resistance to antimicrobial therapy, surface motility, and biofilm formation," Frontiers in microbiology, vol. 9, p. 1902, 2018.
[9] A. R. Lari, A. Ardebili, and A. Hashemi, "AdeR-AdeS mutations & overexpression of the AdeABC efflux system in ciprofloxacin-resistant Acinetobacter baumannii clinical isolates," The Indian journal of medical research, vol. 147, p. 413, 2018.
[10] R. Krasauskas, J. Skerniškytė, J. Armalytė, and E. Sužiedėlienė, "The role of Acinetobacter baumannii response regulator BfmR in pellicle formation and competitiveness via contact-dependent inhibition system," BMC microbiology, vol. 19, pp. 1-12, 2019.
[11] L. Chen, H. Li, H. Wen, B. Zhao, Y. Niu, Q. Mo, et al., "Biofilm formation in Acinetobacter baumannii was inhibited by PAβN while it had no association with antibiotic resistance," MicrobiologyOpen, vol. 9, p. e1063, 2020.
[12] H. Mahmoudi, L. Shokoohizadeh, N. Zare Fahim, A. Mohamadi Bardebari, S. Moradkhani, and M. Y. Alikhani, "Detection of adeABC efllux pump encoding genes and antimicrobial effect of Mentha longifolia and Menthol on MICs of imipenem and ciprofloxacin in clinical isolates of Acinetobacter baumannii," BMC complementary medicine and therapies, vol. 20, pp. 1-7, 2020.
[13] S. S. Gurpinar, D. Kart, and M. Eryilmaz, "The effects of antidepressants fluoxetine, sertraline, and amitriptyline on the development of antibiotic resistance in Acinetobacter baumannii," Archives of Microbiology, vol. 204, pp. 1-10, 2022.
[14] Y. Chen, L. Ai, P. Guo, H. Huang, Z. Wu, X. Liang, et al., "Molecular characterization of multidrug resistant strains of Acinetobacter baumannii isolated from pediatric intensive care unit in a Chinese tertiary hospital," BMC Infectious Diseases, vol. 18, pp. 1-7, 2018.
[15] A. A. Shali, P. J. Jalal, and S. K. Arif, "Dissemination and Genetic Relatedness of Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Isolates from a Burn Hospital in Iraq," Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2022, 2022.
[16] M. K. Qader, "Molecular study of Acinetobacter baumannii using 16S rRNA and blaOXA-51 gene isolated from hospitals in Duhok-Kurdistan region, Iraq," Journal of Duhok University, vol. 24, pp. 19-25, 2021.
[17] M. P. Weinstein and J. S. Lewis, "The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes," Journal of clinical microbiology, vol. 58, pp. e01864-19, 2020.
[18] L. Dortet, L. Poirel, C. Errera, and P. Nordmann, "CarbAcineto NP test for rapid detection of carbapenemase-producing Acinetobacter spp," Journal of clinical microbiology, vol. 52, pp. 2359-2364, 2014.
[19] K. T. Suryavanshi and K. K. Lahiri, "Assessment of RapidecCarba NP test, as screening test to detect carbapenemase, specially metallo-[beta]-lactamase producing Gram negative bacteria at tertiary care centre," IJHSR, vol. 8, pp. 56-61, 2018.
[20] B. Bedenić, R. Ladavac, M. Vranić-Ladavac, N. Barišić, N. Karčić, K. B. Sreter, et al., "False positive phenotypic detection of metallo-beta-lactamases in Acinetobacter baumannii," Acta clinica Croatica, vol. 58, p. 113, 2019.
[21] M. D. Alcántar-Curiel, L. F. García-Torres, M. I. González-Chávez, R. Morfín-Otero, C. Gayosso-Vázquez, M. D. Jarillo-Quijada, et al., "Molecular mechanisms associated with nosocomial carbapenem-resistant Acinetobacter baumannii in Mexico," Archives of medical research, vol. 45, pp. 553-560, 2014.
[22] J. A. Viehman and M. H. Nguyen, "Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections," Drugs, vol. 74, pp. 1315-1333, 2014.
[23] E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D. L. Monnet, et al., "Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis," The Lancet Infectious Diseases, vol. 18, pp. 318-327, 2018.
[24] B. Salehi, Z. Ghalavand, A. Yadegar, and G. Eslami, "Characteristics and diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with drug-resistant clinical isolates of Acinetobacter baumannii," Antimicrobial Resistance & Infection Control, vol. 10, pp. 1-12, 2021.
[25] B. A. Evans and S. G. Amyes, "OXA β-lactamases," Clinical microbiology reviews, vol. 27, pp. 241-263, 2014.
[26] N. D. Ghulam and H. Hamimah, "Emergence of extensive drug-resistant Acinetobacter baumannii in North of Jordan," African Journal of Microbiology Research, vol. 5, pp. 1070-1074, 2011.
[27] H. Hussein, H. J. F. Al-Mathkhury, and A. Sabbah, "Imipenem-Resistant Acinetobacter baumannii isolated from patients and hospitals environment in Baghdad," Iraqi Journal of Science, vol. 54, pp. 803-812, 2013.
[28] N. Obeidat, F. Jawdat, A. G. Al-Bakri, and A. A. Shehabi, "Major biologic characteristics of Acinetobacter baumannii isolates from hospital environmental and patients' respiratory tract sources,"
American journal of infection control, vol. 42, pp. 401-404, 2014.
[29] B. A. Almomani, A. McCullough, R. Gharaibeh, S. Samrah, and F. Mahasneh, "Incidence and predictors of 14-day mortality in multidrug-resistant Acinetobacter baumannii in ventilator-associated pneumonia," The Journal of Infection in Developing Countries, vol. 9, pp. 1323-1330, 2015.
[30] A. Batarseh, A. Al-Sarhan, M. Maayteh, S. Al-Khatirei, and M. Alarmouti, "Antibiogram of multidrug resistant Acinetobacter baumannii isolated from clinical specimens at King Hussein Medical Centre, Jordan: a retrospective analysis," East Mediterr Health J, vol. 21, p. 11, 2015.
[31] A. A. Shali, "Identification of Multidrug-Resistant Genes in" Acinetobacter baumannii" in Sulaimani City-Kurdistan Regional Government of Iraq," Asian Journal of Medical Sciences, vol. 4, pp. 179-183, 2012.
[32] N. H. Hussein, H. J. F. Al-Mathkhury, and M. A. Sabbah, "Identification of imipenem-resistant genes in Acinetobacter baumannii isolated from Baghdad Hospitals," J Med Microb Diagn, vol. 3, p. 170, 2014.
[33] A. R. Ganjo, D. M. Maghdid, I. Y. Mansoor, D. J. Kok, J. A. Severin, H. A. Verbrugh, et al., "OXA-carbapenemases present in clinical Acinetobacter baumannii-calcoaceticus complex isolates from patients in Kurdistan region, Iraq," Microbial drug resistance, vol. 22, pp. 627-637, 2016.
[34] S. H. Radhi and A. H. Al-Charrakh, "Occurrence of MBLs and Carbapenemases among MDR and XDR Acinetobacter baumannii Isolated from Hospitals in Iraq," SCOPUS IJPHRD CITATION SCORE, vol. 10, p. 668, 2019.
[35] N. H. Ahmad and G. A. Mohammad, "Identification of Acinetobacter baumannii and Determination of MDR and XDR Strains," Baghdad Sci J, vol. 17, 2020.
[36] N. H. Mahmood and A. Al-Brefkani, "Molecular Characterisation of Carbapenemase-Producing Acinetobacter baumannii isolates from Hospitalised Patients in Iraq," Journal of Life and Bio Sciences Research, vol. 3, pp. 27-32, 2022.
[37] S.-C. Kuo, S.-C. Chang, H.-Y. Wang, J.-F. Lai, P.-C. Chen, Y.-R. Shiau, et al., "Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program," BMC Infectious Diseases, vol. 12, pp. 1-9, 2012.
[38] L. R. Pancotto, C. S. Nodari, F. P. Rozales, T. Soldi, C. G. Siqueira, A. L. Freitas, et al., "Performance of rapid tests for carbapenemase detection among Brazilian Enterobacteriaceae isolates," brazilian journal of microbiology, vol. 49, pp. 914-918, 2018.
[39] M. Al-Tamimi, H. Albalawi, M. Alkhawaldeh, A. Alazzam, H. Ramadan, M. Altalalwah, et al., "Multidrug-Resistant Acinetobacter baumannii in Jordan," Microorganisms, vol. 10, p. 849, 2022.
[40] Y. Ju, Y.-J. Kim, C. L. Chang, G.-E. Choi, and K.-Y. Hyun, "Relationship between AdeABC Efflux Pump Genes and Carbapenem in Multidrug-resistant Acinetobacter baumannii," Biomedical Science Letters, vol. 27, pp. 59-68, 2021.
[41] I. Abbott, G. M. Cerqueira, S. Bhuiyan, and A. Y. Peleg, "Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies," Expert review of anti-infective therapy, vol. 11, pp. 395-409, 2013.
[42] A. R. JaponiNejad, M. Sofian, and E. Ghaznavi-Rad, "Molecular detection of AdeABC efflux pump genes in clinical isolates of Acinetobacter baumannii and their contribution in imipenem resistance," ISMJ, vol. 17, pp. 815-823, 2014.
[43] H. Khayat, N. Sadeghifard, I. Pakzad, L. Azimi, S. Delfani, K. Sayehmiri, et al., "Determination of different fluoroquinolone mechanisms among clinical isolates of Acinetobacter baumannii in Tehran, Iran," Iranian Red Crescent Medical Journal, vol. 19, 2017.
[44] S. Coyne, P. Courvalin, and B. Périchon, "Efflux-mediated antibiotic resistance in Acinetobacter spp," Antimicrobial agents and chemotherapy, vol. 55, pp. 947-953, 2011.
[45] S. Coyne, G. Guigon, P. Courvalin, and B. Périchon, "Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray," Antimicrobial agents and chemotherapy, vol. 54, pp. 333-340, 2010.
[46] M. Choquet, E. Lohou, E. Pair, P. Sonnet, and C. Mullié, "Efflux Pump Overexpression Profiling in Acinetobacter baumannii and Study of New 1-(1-Naphthylmethyl)-Piperazine Analogs as Potential Efflux Inhibitors," Antimicrobial agents and chemotherapy, vol. 65, pp. e00710-21, 2021.
[47] C.-M. Kim, G. Park, Y. J. Ko, S.-H. Kang, and S. J. Jang, "Relationships between relative expression of RND efflux pump genes, H33342 efflux activity, biofilm-forming activity, and antimicrobial resistance in Acinetobacter baumannii clinical isolates," Japanese Journal of Infectious Diseases, vol. 74, pp. 499-506, 2021.
[48] Y. Shi, X. Hua, Q. Xu, Y. Yang, L. Zhang, J. He, et al., "Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC," Infection, Genetics and Evolution, vol. 80, p. 104185, 2020.
[49] F. Perez, R. Ponce-Terashima, M. D. Adams, and R. A. Bonomo, "Are we closing in on an" elusive enemy"? The current status of our battle with Acinetobacter baumannii," vol. 2, ed: Taylor & Francis, 2011, pp. 86-90.
[50] L. Poirel, B. Berçot, Y. Millemann, R. A. Bonnin, G. Pannaux, and P. Nordmann, "Carbapenemase-producing Acinetobacter spp. in
cattle, France," Emerging infectious diseases, vol. 18, p. 523, 2012.
[51] J. Vila, S. Martí, and J. Sanchez-Céspedes, "Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii," Journal of antimicrobial chemotherapy, vol. 59, pp. 1210-1215, 2007.
[52] C. A. Moubareck, D. H. Halat, C. Akkawi, A. Nabi, M. A. AlSharhan, Z. O. AlDeesi, et al., "Role of outer membrane permeability, efflux mechanism, and carbapenemases in carbapenem-nonsusceptible Pseudomonas aeruginosa from Dubai hospitals: Results of the first cross-sectional survey," International Journal of Infectious Diseases, vol. 84, pp. 143-150, 2019.
[53] M. H. Al-Agamy, K. Jeannot, T. S. El-Mahdy, H. A. Samaha, A. M. Shibl, P. Plésiat, et al., "Diversity of molecular mechanisms conferring carbapenem resistance to Pseudomonas aeruginosa isolates from Saudi Arabia," Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2016, 2016.